{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:09:41Z","timestamp":1791284981577,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Senator Paul D. Wellstone Muscular Dystrophy Research Center"},{"name":"NICHD"},{"name":"NIH","award":["5U54HD066409-05"],"award-info":[{"award-number":["5U54HD066409-05"]}]},{"name":"Jesse\u2019s Journey"},{"DOI":"10.13039\/100015391","name":"The Myositis Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ymthe.2017.02.015","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T09:15:50Z","timestamp":1488878150000},"page":"870-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes"],"prefix":"10.1016","volume":"25","author":[{"given":"Jerry R.","family":"Mendell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarife","family":"Sahenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiah","family":"Al-Zaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda P.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Yalvac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Dvorchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moore-Clingenpeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Shontz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choumpree","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"McColly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Kaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.02.015_bib1","first-page":"240","article-title":"Inclusion body myositis","volume":"25","author":"Yunis","year":"1971","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ymthe.2017.02.015_bib2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coph.2010.03.001","article-title":"Inflammatory muscle diseases: a critical review on pathogenesis and therapies","volume":"10","author":"Dalakas","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib3","first-page":"445","article-title":"Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota","volume":"35","author":"Wilson","year":"2008","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2017.02.015_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mus.20649","article-title":"Myeloid dendritic cells in inclusion-body myositis and polymyositis","volume":"35","author":"Greenberg","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2017.02.015_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.410230111","article-title":"Expression of immunoreactive major histocompatibility complex products in human skeletal muscles","volume":"23","author":"Karpati","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","article-title":"Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T\u00a0cell-mediated cytotoxicity in myopathies","volume":"20","author":"Emslie-Smith","year":"1989","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","article-title":"Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments","volume":"48","author":"Mendell","year":"1991","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410390615","article-title":"Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients","volume":"39","author":"Santorelli","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/116.2.325","article-title":"Mitochondrial DNA deletions in inclusion body myositis","volume":"116","author":"Oldfors","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2017.02.015_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0925-4439(92)90059-V","article-title":"Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR","volume":"1180","author":"Simonetti","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2017.02.015_bib14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.54.5.1033","article-title":"AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis","volume":"54","author":"Banwell","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2009.174276","article-title":"Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid","volume":"80","author":"Muth","year":"2009","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2017.02.015_bib16","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2017.02.015_bib17","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2017.02.015_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2017.02.015_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.410400407","article-title":"Inclusion body myositis: clinical and pathological boundaries","volume":"40","author":"Amato","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00019052-200410000-00006","article-title":"Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis","volume":"17","author":"Dalakas","year":"2004","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0032-1329197","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2012","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib24","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"issue":"2, Suppl 1","key":"10.1016\/j.ymthe.2017.02.015_bib28","first-page":"S123","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib29","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2017.02.015_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ymthe.2017.02.015_bib31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.02.015_bib33","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1371\/journal.pone.0000789","article-title":"Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways","volume":"2","author":"Lee","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.02.015_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/rep.0.1260133","article-title":"Regulation of ovarian function by the TGF-beta superfamily and follistatin","volume":"126","author":"Lin","year":"2003","journal-title":"Reproduction"},{"key":"10.1016\/j.ymthe.2017.02.015_bib35","doi-asserted-by":"crossref","first-page":"15579","DOI":"10.1016\/S0021-9258(18)82296-7","article-title":"Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell","volume":"268","author":"Sugino","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.02.015_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.02.015_bib37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1212\/WNL.44.3_Part_1.442","article-title":"Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing","volume":"44","author":"Tawil","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.21732","article-title":"Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins","volume":"66","author":"Mendell","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.22251","article-title":"Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D","volume":"68","author":"Mendell","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib40","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mus.21420","article-title":"Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy","volume":"40","author":"Viollet","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2017.02.015_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1984.04050160045014","article-title":"Computed tomographic patterns of muscles in neuromuscular diseases","volume":"41","author":"Hawley","year":"1984","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0960-8966(02)00023-8","article-title":"Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1)","volume":"12","author":"Mercuri","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2017.02.015_bib43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1212\/WNL.0b013e318208811f","article-title":"Muscle histology vs MRI in Duchenne muscular dystrophy","volume":"76","author":"Kinali","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/en.2010-0868","article-title":"Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine","volume":"152","author":"Hansen","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymthe.2017.02.015_bib45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4161\/15384101.2014.991572","article-title":"mTOR coordinates protein synthesis, mitochondrial activity and proliferation","volume":"14","author":"Morita","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ymthe.2017.02.015_bib46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1083\/jcb.201109091","article-title":"Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin","volume":"197","author":"Winbanks","year":"2012","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib47","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ncb2329","article-title":"The AMPK signalling pathway coordinates cell growth, autophagy and metabolism","volume":"13","author":"Mihaylova","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tem.2015.02.009","article-title":"Expanding roles for AMPK in skeletal muscle plasticity","volume":"26","author":"Mounier","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2017.02.015_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cytogfr.2009.02.007","article-title":"Activin and related proteins in inflammation: not just interested bystanders","volume":"20","author":"Phillips","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2017.02.015_bib50","doi-asserted-by":"crossref","first-page":"19371","DOI":"10.1074\/jbc.M802585200","article-title":"Myostatin directly regulates skeletal muscle fibrosis","volume":"283","author":"Li","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.02.015_bib51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajpath.2011.04.008","article-title":"Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis","volume":"179","author":"Zhu","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2017.02.015_bib52","doi-asserted-by":"crossref","first-page":"e58554","DOI":"10.1371\/journal.pone.0058554","article-title":"Myostatin suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction","volume":"8","author":"Dong","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.02.015_bib53","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cpf.12259","article-title":"Effects of blood-flow-restricted resistance training on muscle function in a 74-year-old male with sporadic inclusion body myositis: a case report","volume":"36","author":"Jorgensen","year":"2016","journal-title":"Clin. Phys. Funct. Imaging"},{"key":"10.1016\/j.ymthe.2017.02.015_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","article-title":"Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis","volume":"10","author":"Johnson","year":"2009","journal-title":"J.\u00a0Clin. Neuromuscul. Dis."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617300928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617300928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T06:28:56Z","timestamp":1717828136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617300928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1525001617300928"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.015","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}